Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, an expert medical oncology panel led by John L. Marshall, MD, with Jamie E. Chaft, MD, and Scot Niglio, MD, provides a brief overview on the revolutionary changes brought by immuno-oncology to the management of gastrointestinal, thoracic, and genitourinary cancers. Then, the panel answers clinician questions on important topics such as:
Content based on an online CME program supported by an educational grant from Merck Sharp & Dohme Corp.
Link to full program: https://www.clinicaloptions.com/oncology/programs/biomarkers2020
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Medical Oncologist
Bethesda, Maryland
Senior Scientific Director
Senior Clinical Editor
Editorial Contributor
Associate Director, Scientific Services
Director, CME Program Development
Senior Director, Educational Strategy
This program has been made available online.
Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)
From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy into community care
Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)
Update of ATEZO-BRAIN trial evaluating atezolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC with untreated brain metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.